Effect of DSIP In Chronic Pain and Depression The use of DSIP in patients with chronic pain and depression, or both, was another important clinical indication for this neuropeptide
AOD 9604 Dosage and Protocol: What the Research Supports The standard research protocol for AOD 9604 is 300 mcg per day, administered via subcutaneous injection
Sermorelin may be more appropriate when the focus is systemic recovery, growth hormone support, sleep, energy, and body composition
Ultimately, we think that Alpha BRAIN is reasonably priced for a nootropic, but it has some issues with its formulation and how it presents itself to consumers, which gives us pause
note that daily dosing is only for the activation phase of the GLOW protocol (weeks 1-4) , decreasing to 5x per week for the remodeling phase (weeks 5-8), and further reduced to 2-3x per week during maintenance (weeks 9-12)